• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

伊朗幽门螺杆菌对左氧氟沙星和莫西沙星的原发耐药性。

Primary resistance of Helicobacter pylori to levofloxacin and moxifloxacine in Iran.

机构信息

Department of Bacteriology, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran.

出版信息

Intern Emerg Med. 2012 Oct;7(5):447-52. doi: 10.1007/s11739-011-0563-1. Epub 2011 Mar 25.

DOI:10.1007/s11739-011-0563-1
PMID:21437583
Abstract

The increase in the prevalence of antibiotic resistance in Helicobacter pylori had a drastic effect on successful treatment. Up-to-date information on H. pylori antibiotic therapy in Iran is still limited. In this study, we aim to determine the prevalence of antibiotic resistance among the H. pylori strains. Furthermore, the possibility of using fluoroquinolones for antibiotic treatment was investigated. Antral biopsy specimens obtained from dyspeptic patients were investigated for H. pylori. Bacterial culture and susceptibility tests were done based on standard methods. H. pylori ATCC 43504 was used as a quality control. In the current study, 30 H. pylori strains were selected randomly and retested to confirm our susceptibility tests. Of 170 patients, 150 were identified as positive for H. pylori (88.2%). In this study, 150 single colonies of H. pylori strains [81 women (54%), 69 men (46%); mean age 38.6; aged 21-70 years] were collected. Primary resistance of H. pylori isolates were clarithromycin (34%), metronidazole (78.6%), tetracycline (9.3%), amoxicillin (10%), levofloxacin (5.3%) and moxifloxacine (4.6%). In conclusion, our results show that we are confronting a new generation of resistant strains of H. pylori in Iran. This alarming finding indicates an urgent need for introduction of new effective antibiotics in our country. Since the majority of clinicians prefer to continue with the ineffective antibiotics as therapeutic regimens, they must also be prepared to deal with treatment failures.

摘要

幽门螺杆菌抗生素耐药性的流行率增加对治疗的成功产生了巨大影响。目前关于伊朗幽门螺杆菌抗生素治疗的最新信息仍然有限。在这项研究中,我们旨在确定幽门螺杆菌菌株的抗生素耐药率。此外,还研究了使用氟喹诺酮类药物进行抗生素治疗的可能性。从消化不良患者的胃窦活检标本中检测幽门螺杆菌。根据标准方法进行细菌培养和药敏试验。幽门螺杆菌 ATCC 43504 被用作质量控制。在本研究中,随机选择了 30 株幽门螺杆菌菌株并进行了重新测试以确认我们的药敏试验。在 170 名患者中,有 150 名被确定为幽门螺杆菌阳性(88.2%)。在本研究中,共收集了 150 株幽门螺杆菌单菌落[81 名女性(54%),69 名男性(46%);平均年龄 38.6 岁;年龄 21-70 岁]。幽门螺杆菌分离株的原发性耐药性分别为克拉霉素(34%)、甲硝唑(78.6%)、四环素(9.3%)、阿莫西林(10%)、左氧氟沙星(5.3%)和莫西沙星(4.6%)。总之,我们的结果表明,我们在伊朗正面临新一代耐药幽门螺杆菌菌株。这一令人震惊的发现表明,我们迫切需要在我国引入新的有效抗生素。由于大多数临床医生倾向于继续使用无效的抗生素作为治疗方案,他们还必须准备好应对治疗失败。

相似文献

1
Primary resistance of Helicobacter pylori to levofloxacin and moxifloxacine in Iran.伊朗幽门螺杆菌对左氧氟沙星和莫西沙星的原发耐药性。
Intern Emerg Med. 2012 Oct;7(5):447-52. doi: 10.1007/s11739-011-0563-1. Epub 2011 Mar 25.
2
[Regional difference of antibiotic resistance of helicobacter pylori strains in Korea].[韩国幽门螺杆菌菌株抗生素耐药性的区域差异]
Korean J Gastroenterol. 2011 Apr;57(4):221-9. doi: 10.4166/kjg.2011.57.4.221.
3
In vitro antimicrobial susceptibility of Helicobacter pylori to nine antibiotics currently used in Central Italy.意大利中部目前使用的九种抗生素对幽门螺杆菌的体外抗菌敏感性
Scand J Gastroenterol. 2016 Mar;51(3):263-9. doi: 10.3109/00365521.2015.1092577. Epub 2015 Oct 7.
4
[Current value of quinolones in Helicobacter pylori therapy].[喹诺酮类药物在幽门螺杆菌治疗中的当前价值]
Z Gastroenterol. 2011 Aug;49(8):989-96. doi: 10.1055/s-0031-1273390. Epub 2011 Aug 2.
5
High eradication rate of H. pylori with moxifloxacin-based treatment: a randomized controlled trial.基于莫西沙星治疗幽门螺杆菌的高根除率:一项随机对照试验。
Wien Klin Wochenschr. 2007;119(11-12):372-8. doi: 10.1007/s00508-007-0807-2.
6
Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis.莫西沙星和左氧氟沙星三联疗法作为幽门螺杆菌持续感染二线治疗的优势:一项荟萃分析。
Wien Klin Wochenschr. 2010 Jul;122(13-14):413-22. doi: 10.1007/s00508-010-1404-3. Epub 2010 Jul 16.
7
ANTIBIOTIC RESISTANCE SURVEILLANCE OF HELICOBACTER PYLORI AT THE BIOBÍO REGION (CHILE) IN A DECADE.十年间智利比奥比奥地区幽门螺杆菌的抗生素耐药性监测
Arq Gastroenterol. 2019 Oct-Dec;56(4):361-366. doi: 10.1590/S0004-2803.201900000-72.
8
Antimicrobial resistance of Helicobacter pylori strains to five antibiotics, including levofloxacin, in Northwestern Turkey.土耳其西北部幽门螺杆菌菌株对包括左氧氟沙星在内的五种抗生素的耐药性。
Rev Soc Bras Med Trop. 2015 May-Jun;48(3):278-84. doi: 10.1590/0037-8682-0027-2015.
9
In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against Helicobacter pylori isolates in Taiwan, 1998-2007.1998-2007 年台湾幽门螺杆菌分离株对奈莫沙星、替加环素和其他抗菌药物的体外活性。
Eur J Clin Microbiol Infect Dis. 2010 Nov;29(11):1369-75. doi: 10.1007/s10096-010-1009-9. Epub 2010 Jul 25.
10
Role of the preliminary susceptibility testing for initial and after failed therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and esomeprazole.左氧氟沙星、阿莫西林和埃索美拉唑对幽门螺杆菌感染初始治疗及治疗失败后初步药敏试验的作用
Helicobacter. 2006 Aug;11(4):237-42. doi: 10.1111/j.1523-5378.2006.00407.x.

引用本文的文献

1
The prevalence of clarithromycin-resistant isolates: a systematic review and meta-analysis.克拉霉素耐药分离株的流行率:系统评价和荟萃分析。
PeerJ. 2023 Mar 30;11:e15121. doi: 10.7717/peerj.15121. eCollection 2023.
2
Reevaluation of the Efficacy of First Line Regimen for .对……一线治疗方案疗效的重新评估
Clin Exp Gastroenterol. 2020 Jan 22;13:25-33. doi: 10.2147/CEG.S239343. eCollection 2020.
3
Antibacterial activity of lactobacilli probiotics on clinical strains of .乳酸杆菌益生菌对……临床菌株的抗菌活性。 (原文此处不完整)

本文引用的文献

1
Antibiotic resistance of Helicobacter pylori in Mazandaran, North of Iran.伊朗北部马赞达兰幽门螺杆菌的抗生素耐药性。
Helicobacter. 2010 Dec;15(6):505-9. doi: 10.1111/j.1523-5378.2010.00795.x.
2
Treatment of Helicobacter pylori infection 2010.2010 年幽门螺杆菌感染治疗
Helicobacter. 2010 Sep;15 Suppl 1:46-52. doi: 10.1111/j.1523-5378.2010.00774.x.
3
High prevalence of clarithromycin-resistant Helicobacter pylori strains and risk factors associated with resistance in Madrid, Spain.西班牙马德里地区克拉霉素耐药幽门螺杆菌菌株的高流行率及其耐药相关危险因素。
Iran J Basic Med Sci. 2019 Oct;22(10):1118-1124. doi: 10.22038/ijbms.2019.33321.7953.
4
High Prevalence of Antibiotic Resistance in Iranian Isolates: Importance of Functional and Mutational Analysis of Resistance Genes and Virulence Genotyping.伊朗分离株中抗生素耐药性的高流行率:耐药基因功能与突变分析及毒力基因分型的重要性
J Clin Med. 2019 Nov 17;8(11):2004. doi: 10.3390/jcm8112004.
5
Comparison of Levofloxacin-Based, 10-day Sequential Therapy with 14-day Quadruple Therapy for Eradication: A Randomized Clinical Trial.基于左氧氟沙星的10天序贯疗法与14天四联疗法根除幽门螺杆菌的比较:一项随机临床试验
Middle East J Dig Dis. 2018 Oct;10(4):242-248. doi: 10.15171/mejdd.2018.117. Epub 2018 Sep 6.
6
Eradication of in Iran: A Review.伊朗的根除:一项综述。
Middle East J Dig Dis. 2018 Jan;10(1):5-17. doi: 10.15171/mejdd.2017.84. Epub 2017 Sep 21.
7
Call for global vaccine instead of Helicobacter pylori blind antibiotic therapy.呼吁采用全球疫苗而非幽门螺杆菌盲目抗生素治疗。
Ann Afr Med. 2016 Jul-Sep;15(3):154-5. doi: 10.4103/1596-3519.188897.
8
Multicenter Study of Antibiotic Resistance Profile of H. pylori and Distribution of CYP2C19 Gene Polymorphism in Rural Population of Chongqing, China.中国重庆农村人群幽门螺杆菌抗生素耐药谱及CYP2C19基因多态性分布的多中心研究
Gastroenterol Res Pract. 2016;2016:8547686. doi: 10.1155/2016/8547686. Epub 2016 May 9.
9
Updated Helicobacter pylori management in 2015.2015年幽门螺杆菌管理的更新情况。
Saudi J Gastroenterol. 2016 Jan-Feb;22(1):80. doi: 10.4103/1319-3767.173765.
10
Prevalence of antibiotic resistance in Helicobacter pylori: A recent literature review.幽门螺杆菌抗生素耐药性的流行情况:近期文献综述
World J Methodol. 2015 Sep 26;5(3):164-74. doi: 10.5662/wjm.v5.i3.164.
J Clin Microbiol. 2010 Oct;48(10):3703-7. doi: 10.1128/JCM.00144-10. Epub 2010 Jul 28.
4
Patient factors affecting culture of Helicobacter pylori isolated from gastric mucosal specimens.影响胃黏膜标本中分离的幽门螺杆菌培养的患者因素。
Adv Med Sci. 2010;55(2):161-6. doi: 10.2478/v10039-010-0028-1.
5
Gastric cancer in Iran: epidemiology and risk factors.伊朗的胃癌:流行病学和危险因素。
Arch Iran Med. 2009 Nov;12(6):576-83.
6
High prevalence of virulent Helicobacter pylori strains in symptomatic Bulgarian patients.保加利亚有症状患者中致病性幽门螺杆菌菌株的高流行率。
Diagn Microbiol Infect Dis. 2009 Aug;64(4):374-80. doi: 10.1016/j.diagmicrobio.2009.04.005.
7
Prevalence of primary fluoroquinolone resistance among clinical isolates of Helicobacter pylori at a University Hospital in Southern Taiwan.台湾南部某大学医院幽门螺杆菌临床分离株中原发性氟喹诺酮耐药的流行情况。
Helicobacter. 2009 Feb;14(1):61-5. doi: 10.1111/j.1523-5378.2009.00655.x.
8
Helicobacter pylori cagA status and peptic ulcer disease in Iran.伊朗幽门螺杆菌cagA状态与消化性溃疡病
Dig Dis Sci. 2009 Mar;54(3):608-13. doi: 10.1007/s10620-008-0378-8. Epub 2008 Jul 10.
9
dupA as a risk determinant in Helicobacter pylori infection.dupA作为幽门螺杆菌感染中的一个风险决定因素。
J Med Microbiol. 2008 May;57(Pt 5):554-562. doi: 10.1099/jmm.0.47776-0.
10
Prevalence and evolution of Helicobacter pylori resistance to 6 antibacterial agents over 12 years and correlation between susceptibility testing methods.12年间幽门螺杆菌对6种抗菌药物的耐药率及演变情况与药敏试验方法之间的相关性
Diagn Microbiol Infect Dis. 2008 Apr;60(4):409-15. doi: 10.1016/j.diagmicrobio.2007.11.008. Epub 2008 Jan 14.